Entrada Therapeutics

About Entrada Therapeutics

Entrada Therapeutics is dedicated to transforming the lives of patients by developing a new class of intracellular therapeutics. Their mission is to treat devastating diseases using their proprietary EEV™ Platform, which targets previously inaccessible and undruggable disease-causing targets within cells.

Products & Services

EEV™ Platform:A proprietary platform designed to engage and reach previously inaccessible and undruggable disease-causing targets within cells, with broad potential across various therapeutic areas.

Duchenne Muscular Dystrophy Program:A differentiated approach to developing potential treatments for patients with Duchenne Muscular Dystrophy.

Myotonic Dystrophy Type 1 Program:An innovative approach to target intracellular disease-causing elements for patients with Myotonic Dystrophy Type 1.

ENTR-601-50:A novel EEV™-Oligonucleotide construct for the treatment of Exon 50 skip-amenable Duchenne Muscular Dystrophy, with preclinical efficacy studies planned.

ENTR-601-44:A treatment under study (Phase 1/2b) to assess safety and efficacy for patients with DMD amenable to Exon 44 skipping.

Specialties

Intracellular Therapeutics EEV™ Platform Technology Neuromuscular Disorders Rare Diseases Oligonucleotide Delivery

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 100000000 MR: - FA: approximately $100 million FAN: 100000000	D: 2024-06-24 FD: 2024-06-24	3 investors

Registered Direct Offering Latest

2024-06-24

$100.0M

3 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

Dipal Doshi

Chief Executive Officer

LinkedIn (Pro only)

N

Natarajan Sethuraman

President of Research and Development

LinkedIn (Pro only)

N

Nathan J. Dowden

President and Chief Operating Officer

LinkedIn (Pro only)

K

Kory Wentworth

Chief Financial Officer

K

Kerry Robert

Senior Vice President, People

J

Jared Cohen

General Counsel

View 14 more team members with Pro

Unlock Full Team Directory

Recent News